Please select the eligibility criteria that correspond to the clinical trial below.
Title: Impact of Antioxidant (Androferti) Treatment on Sperm DNA Integrity
Brief Summary: Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.


Options:
A: Inclusion criteria:

* Willing to participate in the study and filling out the informed consent form
* should be infertile (no conception after 12 months intercourse without any contraception)
* age 20-45 y.o, idiopathic asthenospermia according to WHO criteria
* normal hormonal profile

Exclusion criteria:

* any infection in genitourinary (GU) tract
* any anatomical abnormality in GU tract
* any chronic disease during last 3 months
* any surgery in GU tract
* consumption of omega-3 fatty acids and/or vitamin E supplements during last 3 months
B: Inclusion Criteria:

1. Referred due to infertility
2. Age: 18-50 years,
3. Non-smoking,
4. Sperm DNA Fragmentation Index \>25%

Exclusion Criteria:

1. Body mass index (BMI) ≥30,
2. FSH outside the normal range of 2-8 IU/L,g)
3. LH outside the normal range of 2-10 IU/L,
4. T \< 10nmol/L
5. Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
6. History of anabolic steroids use,
7. Taking antioxidant supplementation the last six months.
C: Inclusion Criteria:

* All women initiating IVF treatment

Exclusion Criteria:

* Women that have entered the study before
D: Inclusion Criteria:Couple

* 12 or more months of infertility (primary or secondary)
* Heterosexual
* Cohabitating and able to have regular intercourse

Male:

* ≥ 18 years of age
* At least one abnormal semen parameter on a semen analysis within the past 6 months:

  * Sperm concentration ≤15 Million/ml
  * Total motility ≤40%
  * Normal morphology (Kruger) ≤4%
  * DNA fragmentation (SCSA, DNA fragmentation index) \>25%

Female:

* ≥18 years of age and ≤40 years of age
* For women ≥ 35 years of age, evidence of normal ovarian reserve as assessed by menstrual cycle day 3 (+/-2 days) FSH ≤10 IU/L with estradiol ≤ 70 pg/mL, AMH ≥ 1.0 ng/mL, OR antral follicle count \>10 within one year prior to study initiation.
* Evidence of at least one patent fallopian tube as determined by an hysterosalpingogram or laparoscopy showing at least one patent fallopian tube or a saline infusion sonogram showing spillage of contrast material
* Regular cycles defined as ≥25 days and ≤35 days in duration
* Evidence of ovulation including biphasic basal body temperatures, positive ovulation predictor kits, or progesterone level ≥3 ng/ml.

Exclusion Criteria:

* Couple:

  * Previous sterilization procedures (vasectomy, tubal ligation). The prior procedure may affect study outcomes.
  * Planning in vitro fertilization in the next 6 months

Male:

* Sperm concentration \< 5 million/mL on screening semen analysis
* Current use of a medication or drug that would affect reproductive function or metabolism (see Appendix C for list)
* Current multivitamin or herb use (requires 1 month wash-out)
* Current serious medical illnesses, such as cancer, heart disease, or cirrhosis
* Current use of anticoagulants
* Untreated hypothyroidism
* Uncontrolled diabetes mellitus

Female:

* History of surgically or medically confirmed moderate or severe endometriosis
* Body mass index \>35 kg/m2
* Currently pregnant
* History of polycystic ovarian syndrome
* Current serious medical illnesses, such as cancer, heart disease, or cirrhosis
* History of systemic chemotherapy or pelvic radiation
* Current use of a medication or drug that would affect reproductive function or metabolism

Answer: B